Cancer Detection and Diagnosis Research

Active

Assistance listing
93.394
Agency
Grant awards
9,169 $12,947,433,105 in federal obligations

Program facts

Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0849-0-1-550
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The Department of Health and Human Services National Institutes of Health (specifically the National Cancer Institute) funds cancer screening and early detection research, with the most recent award disbursed on September 3, 2026, under Assistance Listing 93.394.

The program supports development of screening and early detection strategies, diagnostic techniques and methods for predicting disease course in cancer patients, diagnostic imaging, tissue specimen analysis, and establishment of tissue resources to facilitate research. Recent awards reflect substantial investment across liquid biopsy platforms (cell-free DNA and RNA biomarkers for melanoma, ovarian, colorectal, hepatocellular, and pancreatic cancers), imaging innovations (MRI contrast agents, photoacoustic imaging, PET imaging of tumor-associated macrophages), point-of-care diagnostic biosensors, and tissue-based detection methodologies including mutation signature extraction and TCR repertoire profiling. The program also funds Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) projects aimed at commercializing detection innovations.

Grant awards are predominantly Project Grants (81% of 7,404 awards), with smaller shares of Cooperative Agreements (15% of 1,384 awards) and Block Grants (4% of 381 awards). The National Cancer Institute dominates funding, providing 3,067 awards worth $9.39 billion in federal dollars obligated, while the broader NIH system (excluding NCI) accounts for 5,833 awards valued at $3.08 billion. Combined federal dollars obligated total $12.95 billion across 9,169 awards since 1977.

Award activity remains steady: the program disbursed 185 awards in 2026 (through September), following 158 in 2025, 203 in 2024, 242 in 2023, and 270 in 2022. Recent awards span $232 thousand to $1.5 million, with representative projects including fluorescent imaging agents for melanoma diagnosis, blood-based biomarkers for early ovarian cancer detection, advanced MRI techniques for brain tumor characterization, and AI-powered platforms for biopsy adequacy assessment.

Multiple grant opportunities remain open or recently posted. The Investigator-Focused Award (R35; PAR-28-037) supports investigator-driven research programs with scientific freedom and funding stability, posted July 30, 2026. Early-stage technology development (RFA-CA-28-001; posted July 14, 2026) solicits proof-of-concept studies on innovative detection platforms. Advanced technology development and validation (RFA-CA-28-002; posted July 14, 2026) supports further refinement of emerging technologies with demonstrated feasibility. Informatics technology opportunities span early-stage development (RFA-CA-27-019), advanced development (RFA-CA-27-020), and sustainment (RFA-CA-27-021) of tools for cancer data management and analysis.

Objective and description

Objective

To improve screening and early detection strategies and to develop accurate diagnostic techniques and methods for predicting the course of disease in cancer patients. Screening and Early Detection research includes development of strategies to decrea

Description

To improve screening and early detection strategies and to develop accurate diagnostic techniques and methods for predicting the course of disease in cancer patients. Screening and Early Detection research includes development of strategies to decrease cancer mortality by finding tumors early when they are more amenable to treatment. Diagnosis research focuses on methods to determine the presence of a specific type of cancer; to predict its course and response to therapy, both a particular therapy or a class of agents; and to monitor the effect of the therapy and the appearance of disease recurrence. These methods include diagnostic imaging and direct analyses of specimens from tumor or other tissues. Support is also provided for establishing and maintaining resources of human tissue to facilitate research. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.

Eligibility

Applicant eligibility

The awardee will be a university, college, hospital, public agency, nonprofit research institution or organization, unit of tribal government, or a for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.

Uses of assistance

Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultants costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel review option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.

Length and time phasing of assistance

Grants and cooperative agreements: Average 3 to 4 years and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or an Electronic Transfer System. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.

How to apply

Criteria for selecting proposals

The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; 2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.

Award procedure

Grants and cooperative agreements are funded based on scientific merit, program relevance and program balance, consistent with NCI and NIH priorities and strategic plans, and are made annually. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.

Time to approval or disapproval

(Regular Grants) Approximately 10 months. SBIR/STTR: About 7-1/2 months. See website: http://grants1.nih.gov/grants/funding/submissionschedule.htm

Renewals

Applications submitted for renewal are reviewed and selected for funding on a competitive basis.

Appeals

A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/not97-232.html

Grant opportunities

Opportunity Status Posted Applications due
Investigator-Focused Award (Parent R35) PAR-28-037 Forecasted —
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-28-003 Forecasted —
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-28-001 Forecasted —
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-28-002 Forecasted —
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) RFA-CA-27-003 Forecasted —
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-27-089 Forecasted —
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) PAR-27-088 Forecasted —
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) PAR-27-009 Forecasted —
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) RFA-CA-26-010 Forecasted —
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed) PAR-26-129 Past —
NIH Research Program Projects (Parent P01 Clinical Trial Optional) PA-27-061 Open
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
NIH Research Educational Program - Mentoring Activities & Networks (Parent R25/UE5 - Clinical Trial Not Allowed) PA-27-035 Open
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed) RFA-CA-28-004 Open
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) PAR-26-091 Forecasted —
Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) RFA-AI-27-018 Open
Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed) PAR-28-090 Open
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) RFA-CA-27-005 Open
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) PAR-27-072 Open
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-27-002 Open
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-27-001 Open
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-26-001 Open
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-021 Closed
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-020 Closed
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) RFA-CA-27-019 Open
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) PA-27-100 Open
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) PA-27-102 Open
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) PA-27-101 Open
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) PAR-27-078 Open
Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) FOR-CA-25-086 Past —
Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed) FOR-CA-25-087 Past —
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) PAR-27-098 Open
Implementation and Evaluation of Databases to Examine AIDS RFA-AI-28-025 Forecasted —
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional) PAR-25-324 Open
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) RFA-CA-25-005 Closed
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) RFA-CA-25-007 Closed
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) RFA-CA-25-006 Closed
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-25-337 Open
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) PAR-25-338 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) PA-25-304 Open
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-25-301 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) PA-25-306 Open
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-25-003 Closed
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-25-001 Closed
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-25-004 Closed
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-25-002 Closed
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) PAR-25-346 Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) PAR-25-321 Open
Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) RFA-HG-25-007 Closed
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) PAR-25-298 Open
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Award Recipient Federal obligations Awarded
Developing mutation signature extraction (MSE) for human tissues R61CA309676 Duke University $232,297
Development of manufacturing controls for ORL1: a fluorescent imaging agent for in vivo molecular imaging of melanomas R44CA306680 Orlucent, Inc. $1,556,529
Intercepting ovarian cancer at its earliest stage: validation of TU-stroma as a blood-based diagnostic biomarker R01CA318082 Hoag Memorial Hospital Presbyterian $541,081
Imaging-computational framework for guiding treatment of HGG: an ohsv clinical trial R01CA313500 University Of Alabama At Birmingham $643,827
Developing molecular diagnostic methods for cervical cancer R01CA311189 University Of Illinois $665,257
Cfdna fragmentomes for non-invasive early detection of HCC R01CA316223 The Johns Hopkins University $645,435
Transcriptomic molecular risk classification for children with b cell acute lymphoblastic leukemia UH2CA312695 The Children's Hospital Of Philadelphia $350,860
Validation of a liquid biopsy assay for early detection of lymphoma in people with HIV UH2CA308227 Yale Univ $279,018
Quantifiable TCR repertoire changes in pre-diagnostic blood specimens among high-grade ovarian cancer patients U01CA299369 The Children's Hospital Of Philadelphia $610,970
Optimization of a single cell multi-omic analysis platform for circulating and therapeutic immune cells R61CA315160 The Medical University Of South Carolina $211,778

Latest 10 of 9,169 listed here. See the rest on GovTribe.

Top recipients by federal obligations

10 of 965 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $565,699,505
FY2025 $1,072,117,215
FY2024 $1,231,329,539
FY2023 $1,380,948,503
FY2022 $1,148,873,421
FY2021 $979,668,308
FY2020 $534,460,718
FY2019 $445,857,118
FY2018 $426,477,747
FY2017 $400,904,895
FY2016 $390,347,617
FY2015 $369,626,836
FY2014 $345,405,710
FY2013 $350,607,243
FY2012 $355,012,045
FY2011 $339,830,008
FY2010 $318,607,243
FY2009 $279,095,213
FY2008 $116,577,038
FY2007 $189,395,924
FY2006 $299,141,882
FY2005 $268,005,655
FY2004 $264,421,057
FY2003 $225,395,329
FY2002 $227,092,653
FY2001 $110,481,610
Show all 26

Quick answers

What is Assistance Listing 93.394?

Assistance Listing 93.394 is Cancer Detection and Diagnosis Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Cancer Detection and Diagnosis Research?

Its CFDA number is 93.394: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.394 awarded?

9,169 grant awards under 93.394 have obligated $12,947,433,105 in federal funds to 965 recipients.

Who receives the most funding from 93.394?

The recipients obligated the most under Cancer Detection and Diagnosis Research are Fred Hutchinson Cancer Center ($471,795,010), The Regents Of The University Of California. San Francisco ($432,959,437) and The Leland Stanford Junior University ($387,606,334).

How much did 93.394 obligate in fiscal year 2025?

Grants under 93.394 obligated $1,072,117,215 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.394?

37 of the latest 50 opportunities under 93.394 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program